Business
Syndax Announces Participation in Cowen 2nd Annual Virtual Oncology Innovation Summit
WALTHAM, Mass., May 13, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical
About this update from Syndax Pharmaceuticals, Inc.
[{"type":"text","content":"WALTHAM, Mass., May 13, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (\"Syndax,\" the \"Company\" or \"we\") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in the Cowen 2nd Annual Virtual Oncology Innovation Summit on Thursday, May 20, 2021 at 12:00 p.m. ET.\nA live webcast of the presentation can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay of the event will also be available for a limited time.\nAbout Syndax Pharmaceuticals, Inc. \nSyndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company's pipeline includes SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, and entinostat, a class I HDAC inhibitor. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn. \nSyndax Contacts\nInvestor ContactMelissa ForstArgot [email protected] Tel 212.600.1902\nMedia ContactTed Held [email protected] Tel 212.798.9842\nSNDX-G\n View original content:http://www.prnewswire.com/news-releases/syndax-announces-participation-in-cowen-2nd-annual-virtual-oncology-innovation-summit-301290613.html\nSOURCE Syndax Pharmaceuticals, Inc.","length":3114,"tagName":"div"}]